Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

被引：0
|
作者：
Bally, Cecile [1 ]
Ades, Lionel [2 ]
Renneville, Aline [3 ]
Preudhomme, Claude [4 ]
Mozziconacci, Marie-Joelle [5 ]
de The, Hugues [6 ]
Lehmann-Che, Jacqueline [6 ]
Fenaux, Pierre [2 ]
机构：
[1] Hop Avicenne, Hematol Clin, F-93009 Bobigny, France
[2] Univ Paris 13, Hop Avicenne, AP HP, Dept Hematol, Paris, France
[3] CHRU Lille, Ctr Biol Pathol, Lab Hematol, Lille, France
[4] Univ Lille, CHRU Lille, Lille, France
[5] Inst J Paoli I Calmettes, Lab Mol Biol & Cytogenet, F-13009 Marseille, France
[6] Univ Paris, Hosp St Louis, F-75252 Paris, France
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.1706.1706
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1706
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Role in tumorigenesis of silent mutations in the TP53 gene
    Strauss, BS
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2000, 457 (1-2) : 93 - 104
  • [42] TP53 Gene Mutations in Prostate Cancer Progression
    Ecke, Thorsten H.
    Schlechte, Horst H.
    Schiemenz, Katrin
    Sachs, Markus D.
    Lenk, Severin V.
    Rudolph, Birgit D.
    Loening, Stefan A.
    ANTICANCER RESEARCH, 2010, 30 (05) : 1579 - 1586
  • [43] Profile of TP53 gene mutations in sinonasal cancer
    Holmila, Reetta
    Bornholdt, Jette
    Suitiala, Tuula
    Cyr, Diane
    Dictor, Michael
    Steiniche, Torben
    Wolff, Henrik
    Wallin, Hakan
    Luce, Daniele
    Husgafvel-Pursiainen, Kirsti
    MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2010, 686 (1-2) : 9 - 14
  • [44] TP53 mutations are not prognostic independent indicators in bladder cancer
    Agnese, V.
    Corsale, S.
    Augello, C.
    Bruno, L.
    Calo, V.
    Cammareri, P.
    Cascio, S.
    Gargano, G.
    Gregorio, V.
    Gullo, A.
    La Rocca, G.
    Sisto, P. S.
    Valerio, M. R.
    Di Fede, G.
    Martorana, A.
    Bazan, V.
    Russo, A.
    ANNALS OF ONCOLOGY, 2005, 16 : 152 - 152
  • [45] TP53 mutations as a prognostic factor in women with breast cancer
    Marie Lofthouse
    Nature Clinical Practice Oncology, 2005, 2 (9): : 428 - 429
  • [46] The prognostic value of TP53 and tumor suppressor gene mutations in temozolomide-treated IDH1 mutant low-grade glioma
    Salem, Yahia E.
    Abu Alragheb, Bayan O.
    CANCER RESEARCH, 2024, 84 (06)
  • [47] TP53 mutations in low-risk MDS patients with isolated del(5q)
    Belickova, M.
    Vesela, J.
    Cermak, J.
    Dostalova, M. M.
    Krejcik, Z.
    Stara, E.
    Zemanova, Z.
    Jonasova, A.
    LEUKEMIA RESEARCH, 2013, 37 : S27 - S28
  • [48] The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis
    Fisher, Oliver M.
    Lord, Sarah J.
    Falkenback, Dan
    Clemons, Nicholas J.
    Eslick, Guy D.
    Lord, Reginald V.
    GUT, 2017, 66 (03) : 399 - 410
  • [49] The Prognostic Value of TP53 Mutations in Adult Acute Myeloid Leukemia: A Meta-Analysis
    Qin, Guoxiang
    Han, Xueling
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2023, 50 (03) : 234 - 244
  • [50] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
    A Stengel
    W Kern
    T Haferlach
    M Meggendorfer
    A Fasan
    C Haferlach
    Leukemia, 2017, 31 : 705 - 711
12345